CARMA3 is crucial for EGFR-induced activation of NF-κB and tumor progression

79Citations
Citations of this article
60Readers
Mendeley users who have this article in their library.

Abstract

EGF activates NF-κB, and constitutively activated NF-κB contributes to EGFR mutation-associated tumorigenesis, but it remains unclear precisely how EGFR signaling leads to NF-κB activation. Here we report that CARMA3, a caspase recruitment domain (CARD)-containing scaffold molecule, is required for EGF-induced NF-κB activation. CARMA3 deficiency impaired the activation of the IKK complex following EGF stimulation, resulting in a defect of EGF-induced IkBa phosphorylation and NF-κB activation. We found that CARMA3 and Bcl10 contributed to several characteristics of EGFR-associated malignancy, including proliferation, survival, migration, and invasion. Most importantly, CARMA3 contributed to tumor growth in vivo. Our findings elucidate a crucial link between EGFR-proximal signaling components and the downstream IKK complex, and they suggest a new therapeutic target for treatment of EGFR-driven cancers. ©2011 AACR.

Cite

CITATION STYLE

APA

Jiang, T., Grabiner, B., Zhu, Y., Jiang, C., Li, H., You, Y., … Lin, X. (2011). CARMA3 is crucial for EGFR-induced activation of NF-κB and tumor progression. Cancer Research, 71(6), 2183–2192. https://doi.org/10.1158/0008-5472.CAN-10-3626

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free